News

Under the licensing agreement, Scandinavian Gene Synthesis (SGS) will have rights to use their cGMP manufacturing capabilities to make and sell molecular diagnostic products incorporating the Nanogen molecular

The open-label, Simon two-stage study is designed to evaluate the safety and efficacy of the combination of bavituximab with the chemotherapy drugs carboplatin and paclitaxel in non-small cell

Mr Hen is a managing director at Warburg Pincus, a private equity firm. He focuses on investments in biotechnology and pharmaceuticals, including pharmaceutical outsourcing. Dr Zhao, one of

The compound proved to be least toxic and extremely effective in controlling the growth of SF295 human glioblastoma xenografts, the company said. According to PhytoMedical, in all cases

According to the company, this measure is intended to maintain the company’s emphasis on its active preclinical and clinical programs, while conserving the company resources. The company is

For the fourth quarter of 2008, total revenues were $4.34 million, compared to $1.78 million in the same quarter of 2007. For 2008, total revenues were $14.97 million,

SNS-01 is a nano-encapsulated combination therapy of Factor5A and an siRNA against Factor 5A. These studies, undertaken to determine the efficacy, maximum tolerated dose and the feasibility of

This agreement gives Rhei the first option to license the exclusive rights for Skinvisible’s dermatology products for the territory of China, Hong Kong and Taiwan. Specifically the agreement

For the fourth quarter of 2008, total revenue was $811.3 million, up 2.8%, on robust sales to clinical diagnostics customers, partially offset by a decline in Life Sciences